BOSULIF vs GLEEVEC

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. BOSULIF and GLEEVEC are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	BOSULIF	GLEEVEC
Rating	New	70/100
Pharmacy pays	—	~$25.80 /30
Type	RX	RX
Active ingredient	BOSUTINIB MONOHYDRATE	IMATINIB MESYLATE
Manufacturer	Pf Prism Cv	Novartis
Dosage forms	Capsule, Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Bcr-Abl Positive Chronic Myelogenous Leukemia	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

bosulif gleevec

Rating

New

70/100

Pharmacy pays

—

~$25.80 /30

Type

Active ingredient

BOSUTINIB MONOHYDRATE

IMATINIB MESYLATE

Manufacturer

Pf Prism Cv

Novartis

Dosage forms

Capsule, Tablet

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Bcr-Abl Positive Chronic Myelogenous Leukemia

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

What is the difference between Bosulif and Gleevec?

Bosulif contains Bosutinib Monohydrate, while Gleevec contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.